To conduct a meta-analysis on the treatment of tumor-related depression with Radix Bupleuri plus Longgu Muli Decoction，in order to understand the clinical efficacy and safety of such treatment.Methods:Published randomized controlled clinical trials(RCTs)of Radix Bupleuri plus Longgu Muli Decoction in the treatment of tumor-related depression were collected，and the eligible studies were meta-analyzed with RevMan5.3 to evaluate the clinical efficacy and safety of Radix Bupleuri plus Longgu Muli Decoction in the treatment of tumor-related depression.Results:A total of 15 studies met eligibility criteria and was included，with a total sample size of 1 568.Compared with the control group，the reduction of HAMD score in the experimental group was more significantly lower，and the difference was statistically significant [MD=-5.11，95%CI(-7.39 to -2.83)，P<0.000 01].Adverse reactions were less frequent and the difference was statistically significant [RR=0.21，95%CI(0.11 to 0.41)，P<0.000 01].The total effective rate was higher and the difference was statistically significant [RR=1.14，95%CI(1.07 to 1.22)，P=0.000 1].The improvement in quality of life score was even more significant，with a statistically significant difference [RR=0.21，95%CI(0.11 to 0.41)，P<0.000 01].Conclusion:Radix Bupleuri plus Longgu Muli Decoction has significant effects on tumor-related depression and has its unique advantages compared with western anti-depression drugs.